Bispecific and T-cell engager oncology platforms

Across the group, bispecific and T-cell engager platforms are being pushed toward earlier lines of therapy and broader indications rather than treated as late-line niche tools. AMGN frames BLINCYTO, IMDELLTRA and xaluritamig as a connected platform, with Bradner noting BLINCYTO's lessons on moving to earlier lines and Gordon citing new data recasting BLINCYTO as standard of care in Ph-negative B-cell ALL, while IMDELLTRA targets the 8,000 to 10,000 patients who progress annually to second-line extensive-stage small cell lung cancer [m2374, m2375, m2387, m2489, m2477, m2478, m2479]. GILD is leaning on Kite's manufacturing and turnaround-time advantages, with O'Day and Berger both pointing to anetocel's profile moving toward earlier-line multiple myeloma use, and Berger separately highlighting KITE-363's dual CD19/CD20 targeting for deeper responses, plus a new IND extending it into B cell-driven autoimmune disease, a divergence from the pure-oncology focus at AMGN and PFE [m2398, m2417, m2415, m2416]. PFE's approach centers on in-licensing, with Bourla and Boshoff pointing to SSGJ-707, a PD-1 VEGF bispecific from 3SBio, where ESMO Phase II data showed close to 60% response rate combined with mFOLFOX6 in first-line metastatic colorectal cancer [m2319, m2320, m2349]. Bourla frames Pfizer's multi-specific antibody experience as the basis for executing on 707 going forward [m2320].

Amgen calls IMDELLTRA the first bispecific T-cell engager approved for a common solid tumor, part of a platform including BLINCYTO and xaluritamig. [m2374, m2375] Bradner said BLINCYTO lessons are moving therapies from later to earlier lines of therapy to improve efficacy with reduced tumor burden. [m2387] In 2025 Bradner and Gordon reaffirmed growth potential across BLINCYTO, IMDELLTRA and xaluritamig, with Gordon citing new data redefining BLINCYTO as standard of care in Ph-negative B-cell ALL. [m2489, m2477, m2478] Gordon noted 8,000 to 10,000 patients annually progress to second-line extensive-stage small cell lung cancer, the opportunity IMDELLTRA targets. [m2479]

O'Day said anetocel's clinical profile plus Kite's manufacturing and turnaround time position Gilead strongly for multiple myeloma. [m2398] Berger later reinforced this, saying the company remains confident in anetocel's efficacy and safety profile and Kite's manufacturing capabilities, with a positive step toward earlier line settings. [m2417] Berger stated KITE-363, targeting both CD19 and CD20, could offer deeper, more sustained responses and overcome certain resistance mechanisms in oncology. [m2415] Berger said the company filed an IND to also evaluate KITE-363 in B cell-driven autoimmune diseases, expanding beyond the oncology use. [m2416]

Pfizer licensed SSGJ-707, a PD-1 VEGF bispecific, from 3SBio, calling it a strong complement to its oncology portfolio. [m2319, m2320] Bourla cited Phase II first-line metastatic colorectal cancer data shared at ESMO as encouraging for SSGJ-707. [m2319] Boshoff detailed that ESMO data, reporting a response rate close to 60% for the combo with mFOLFOX6 chemotherapy in first-line metastatic colorectal cancer. [m2349] Bourla said Pfizer's deep experience in multi-specific antibody development supports executing on 707 going forward. [m2320]